Airways Disorders Network
-
Advancements in pediatric airway evaluation
Pediatric airway anatomy evaluation continues to evolve with the development of newer technologies such as dynamic volumetric CT scans.
-
Strengthening more than just airways
Emerging research reveals that nutrition and exercise are two powerful yet underutilized tools in managing bronchiectasis.
-
Expanding treatments for COPD management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.
-
AI applications in pediatric pulmonary, sleep, and critical care medicine
Artificial intelligence (AI) refers to the science and engineering of making intelligent machines that mimic human cognitive functions, such as learning and problem solving.1AI tools are being increasingly utilized in […]
-
Bronchiectasis: A call to action
Bronchiectasis is an extremely heterogeneous airways disease, making it difficult to study. For years, the noncystic fibrosis (CF) bronchiectasis community has been trying to organize to provide better care for […]
-
Expanding recommendations for RSV vaccination
Respiratory syncytial virus (RSV) has been increasingly recognized as a prevalent cause of lower respiratory tract infection (LRTI) among adults in the United States. The risk of hospitalization and mortality […]
-
Severe early-life respiratory infections heighten pediatric OSA risk
Children with severe lower respiratory tract infections (LRTIs) within the first 2 years of life had a 2.06-fold increased risk of developing pediatric OSA by age 5, according to a […]
-
Eradicating uncertainty: A review of Pseudomonas aeruginosa eradication in bronchiectasis
Bronchiectasis patients have dilated airways that are often colonized with bacteria, resulting in a vicious cycle of airway inflammation and progressive dilation. Pseudomonas aeruginosa is a frequent airway colonizer and […]
-
Emerging role of biologics in COPD: A new direction
Remodeling of airways and destruction of parenchyma by immune and inflammatory mechanisms are the leading cause of lung function decline in patients with COPD. Type 2 inflammation has been recognized […]
